尾盘，突然暴涨！

Market Overview - A-shares showed mixed performance today, with the Shanghai Composite Index declining by 0.26% to 3860.5 points, while the Shenzhen Component Index rose by 0.63% to 13005.77 points, and the ChiNext Index increased by 1.52% to 3066.18 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 230.34 billion yuan, a decrease of 245.2 billion yuan compared to the previous day [1] Automotive Sector - The automotive industry chain stocks experienced a strong rally, with Haon Electric (301488) hitting the daily limit and reaching a new high, while Wanxiang Qianchao (000559) and Zhejiang Shibao (002703) also reached their daily limits [2][3] - The Ministry of Industry and Information Technology and other departments recently released a plan to promote the industrial application of intelligent connected vehicles, which includes pilot projects for vehicle-road-cloud integration and encourages the production of L3-level vehicles [4][5][6] Energy Storage Sector - The energy storage concept stocks surged, with companies like Tengya Precision (301125) and Ningde Times (300750) reaching new historical highs, with Ningde Times trading volume exceeding 25.59 billion yuan [7][8] - The National Development and Reform Commission and the National Energy Administration announced a plan for new energy storage construction, aiming for over 100 million kilowatts of new installed capacity within three years, which could lead to direct investment of approximately 250 billion yuan [9] Semiconductor Sector - The semiconductor sector was active, with companies like Shengbang Technology (300661) and Shanghai Beiling (600171) hitting their daily limits [10][11] - Recent U.S. trade actions have increased domestic manufacturers' willingness to replace imports, and the ongoing anti-dumping investigations may create a favorable market environment for local firms [12] Biotechnology Sector - Yaoke Ankang's stock price surged over 110% in a single day, with a cumulative increase of nearly 500% over the past four trading days, following the announcement of clinical trial approvals for its core product [13]